FDA Announces the Approval of First Version of Generic Pravachol

The Food and Drug Administration (FDA) has announced the approval of the first generic version of Bristol-Myers Squibb’s Pravachol (Pravastatin Sodium Tablets), which the agency sees as “an important step in the agency’s effort to increase the availability of lower-cost generic medications.”

Pravastatin is indicated for “the treatment of individuals with high cholesterol levels (hyperlipidemia) or who are at increased risk for atherosclerosis-related cardiac and cardiovascular events, such as heart attack and stroke in which high cholesterol levels are a factor.”

In 2005, Pravachol ranked 22nd among brand-name prescription drugs with U.S. sales totaling $1.3 billion. The Bristol-Myers Squibb’s patent for the drug expired on April 20. Pravastatin Sodium Tablets (10mg, 20mg and 40mg) are manufactured by TEVA Pharmaceuticals in Kfar Sava, Israel.

“This approval is another example of our agency’s endeavor to counter rising health care costs by approving safe and effective generic alternatives as soon as the law permits,” said Dr. Scott Gottlieb, Deputy Commissioner for Medical and Scientific Affairs. “Pravastatin is a widely-used cholesterol-lowering agent, and its generic version can bring significant savings to the millions of Americans with this disease.”

According to the FDA release: “Generic drug products are used to fill over 50 percent of all prescriptions and since they cost a fraction of the price of brand name drugs, the economic impact of FDA’s generic drug program is profound. With this in mind, the Office of Generic Drugs (OGD) continues working expeditiously to review and take action on generic drug applications as quickly as possibly. In addition there are several process improvements underway at the Agency to facilitate in the review of generic drug applications.”

Another announced goal of the FDA is to have OGD consider “several simple, yet innovative new policies that could lead to the overall reduction of review time. These include new review formats which allow for overall risk assessments for individual applications in order to dictate the level of OGD review need for subsequent product changes. When fully implemented this has the potential to reduce supplements by 80 percent and reduce Office expenditures of time and money.”

This entry was posted in Health Concerns. Bookmark the permalink.

© 2005-2019 Parker Waichman LLP ®. All Rights Reserved.